Allmed Medical Products Co Ltd

Allmed Medical Products Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.49, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which suggests potential liquidity risk. The company's debt-to-equity ratio of 0.28 indicates a conservative capital structure, with equity significantly outweighing debt.

In terms of profitability, Allmed Medical Products Co Ltd reports a return on equity (ROE) of 2.86% and a return on assets (ROA) of 1.83%. These figures are below the industry median for medical equipment and supplies companies, suggesting that the company is underperforming in terms of capital efficiency and asset utilization. The company's net income of 93.1 million CNY is supported by an operating income of 120.6 million CNY, but its gross profit margin of 28.2% is in line with industry norms.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no material geographic diversification beyond China. This concentration increases exposure to domestic economic and regulatory risks, particularly in the healthcare sector. No material revenue is attributed to international operations, and the company does not disclose any significant customer concentration.

Looking ahead, the company's revenue is expected to grow in the current fiscal year, with a projected increase in operating cash flow driven by improved production efficiency and cost control. However, the company's capital expenditures are negative, indicating a reduction in investment in new facilities or equipment, which may limit long-term growth potential. The company's operating cash flow of 327.2 million CNY supports its liquidity position but does not fully offset its long-term debt obligations.

The company faces moderate risk from liquidity constraints, as its net cash is negative after subtracting total debt. While dilution risk is currently low, the company's capital structure and financing activities suggest that it may need to raise additional capital in the future to support growth or debt servicing. No recent equity issuance or dilutive financing events have been disclosed, but the company's reliance on debt financing could increase in the event of rising interest rates or declining cash flow.

Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and improving operational efficiency. The company has not disclosed any material legal or regulatory issues, but it is subject to the broader risks facing the Chinese healthcare equipment industry, including pricing pressures and regulatory scrutiny.

Allmed Medical Products Co Ltd (002950.SZ) has undergone a significant update to its corporate taxonomy, now formally classified under the "Healthcare" economic sector and "Healthcare Services & Equipment" activity. This structural clarification provides a clearer framework for understanding the company's operational focus within the broader medical industry landscape. Concurrently, the company's risk profile has been established with specific assessments for dilution and liquidity. The dilution risk is currently rated as "low," indicating a stable share structure with minimal immediate threat of equity erosion for existing shareholders. In contrast, the liquidity risk assessment has been set at "medium." This designation suggests that while the company maintains operational viability, investors should monitor trading volumes and market depth, as liquidity conditions may present moderate challenges for large-scale transactions. These updates collectively refine the analytical baseline for Allmed Medical Products, offering stakeholders a more precise view of its sector alignment and associated financial risks. The combination of low dilution risk and medium liquidity risk, alongside its confirmed healthcare classification, helps contextualize the company's position for future investment analysis. [doc:002950.sz-ha-financials]

Cash conversion ratio of 3.51 is best-in-class compared to the 0.84 cohort median.

Debt-to-equity ratio of 0.28 is below the 0.20 cohort median, indicating conservative leverage.

The company faces high credit risk according to the provided risk flag assessment.

Revenue ¥2.93B; Operating income ¥505.8M.

• ▍Revenue ¥2.93B
• ▍Operating income ¥505.8M
• ▍Net margin 14.7%